Blood metabolite profiles and risk of developing breast cancer in PLCO.
1. Examine each of ~600 identified metabolites and associated metabolic profiles in prediagnostic T1 serum in relation to subsequent breast cancer incidence
2. Examine metabolite levels and metabolic profiles in samples proximal to diagnosis in relation to breast cancer incidence
Robert Hoover (DCEG, OD)
Joshua Sampson (DCEG, BB)
Regina Ziegler (DCEG, OD)
Rashmi Sinha (DCEG, NEB)
Charles Matthews (DCEG, NEB)
Steven Moore (Extramural)
Mary Playdon (Huntsman Cancer Institute)
Yei-Eun Shin (NCI)
-
A metabolomic investigation of serum perfluorooctane sulfonate and perfluorooctanoate.
Rhee J, Loftfield E, Albanes D, Layne TM, Stolzenberg-Solomon R, Liao LM, Playdon MC, Berndt SI, Sampson JN, Freedman ND, Moore SC, Purdue MP
Environ Int. 2023 Sep 9; Volume 180: Pages 108198 PUBMED -
Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Chang VC , Rhee J , Berndt SI , Moore SC , Freedman ND , Jones RR , Silverman DT , Gierach GL , Hofmann JN , Purdue MP
Int J Cancer. 2023 Feb 26 PUBMED -
A Metabolomics Analysis of Body Mass Index and Postmenopausal Breast Cancer Risk.
Moore SC, Playdon MC, Sampson JN, Hoover RN, Trabert B, Matthews CE, Ziegler RG
J. Natl. Cancer Inst. 2018 Jun; Volume 110 (Issue 6): Pages 588-597 PUBMED -
Using Metabolomics to Explore the Role of Postmenopausal Adiposity in Breast Cancer Risk.
Lasky-Su JA, Zeleznik OA, Eliassen AH
J. Natl. Cancer Inst. 2018 Jun; Volume 110 (Issue 6): Pages 547-548 PUBMED -
Nutritional metabolomics and breast cancer risk in a prospective study.
Playdon MC, Ziegler RG, Sampson JN, Stolzenberg-Solomon R, Thompson HJ, Irwin ML, Mayne ST, Hoover RN, Moore SC
Am. J. Clin. Nutr. 2017 Aug; Volume 106 (Issue 2): Pages 637-649 PUBMED